Approved drugGlucagon analog (glucagon receptor agonist)

Dasiglucagon

Zegalogue, ZP4207

Common dose: 0.6 mg once, as needed
Cycle: As needed
Form: Ready-made pens

A lab-made glucagon analog with 7 of glucagon’s 29 amino acids swapped, which keeps it stable as a ready-to-use liquid. Like glucagon, it makes the liver release stored sugar, raising blood sugar within about 10 minutes.

Evidence. FDA-approved in March 2021 as Zegalogue, a ready-to-use rescue injection for severe low blood sugar in diabetes (since June 2026, for anyone weighing at least 20 kg), and authorized in the EU in July 2024. Novo Nordisk, its US marketer, ended US sales in January 2026, and FDA lists it as discontinued. A pump-infused version for congenital hyperinsulinism in children was turned down twice by FDA over a contract manufacturing plant (2023, 2024); Zealand Pharma plans to refile in late 2026.

What it’s used for

Approved uses first, then uses tested in people, then claims that rest on animal studies or user reports.

Severe low blood sugar in diabetes: LabelZegalogue is approved for adults and anyone with diabetes weighing at least 20 kg. In two adult trials, median recovery took 10 minutes vs 35–40 minutes on placebo.
Congenital hyperinsulinism in children: TrialNot approved: FDA turned it down twice (2023, 2024) over a contract plant. In one trial its main finger-stick measure failed, though monitor-recorded lows fell 43%; in infants it cut IV glucose needs.
Low blood sugar after gastric bypass: TrialUnapproved: in a 4-week crossover trial of 24 adults, self-injected low doses cut time below 70 mg/dL by 33% vs placebo and corrected 97% of lows within 15 minutes.
Mild lows in type 1 diabetes: TrialUnproven: in a 2-week trial of 24 adults, low doses by pen sped recovery from lows by 44% and cut carbohydrate eaten by 11%; time spent low didn’t differ significantly.
Dual-hormone insulin pumps: TrialExperimental: in a 7-day home crossover of 10 adults, a pump adding dasiglucagon to insulin kept glucose in range 79% of the time vs 72% with insulin alone.

Label: an approved use. Trial: tested in people, with the result.

Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.

Status

Approval: Approved in the US in March 2021 as Zegalogue for severe low blood sugar in diabetes; since June 2026 the label covers adults and children who weigh at least 20 kg. Novo Nordisk ended US sales in January 2026 and FDA lists both presentations as discontinued; it isn’t approved for congenital hyperinsulinism.
Approval history: 2021US FDA: Zegalogue: severe low blood sugar in diabetes, ages 6 and up
2024EU (EMA): Zegalogue: severe low blood sugar in diabetes, ages 6 and up
2026US FDA: Zegalogue: US sales ended in January; listed as discontinued
2026US FDA: Zegalogue: label widened to anyone with diabetes weighing 20 kg or more
European Union: Zegalogue was authorized EU-wide in July 2024 (ages 6 and up). Zealand Pharma asked in early 2026 to withdraw it; EMA still listed it as authorized in October 2026.
United Kingdom: No marketing authorization found.
Canada: No marketing authorization; Health Canada’s Drug Product Database lists no dasiglucagon product.
Australia: No marketing authorization found; dasiglucagon isn’t named in the Poisons Standard (October 2026).
Sport (WADA 2026): Not banned in sportNot named on the 2026 list, and S0 doesn’t apply to an approved drug.

Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.

How it works

LabelBased on the product label.

Not known

Effects of long-term pump infusion, studied only in children with congenital hyperinsulinism, are still being assessed; one newborn developed necrolytic migratory erythema, a severe rash. How people over 65 respond is unknown.

Protocol

Label

Zegalogue

0.6 mg injected under the skin of the lower belly, buttocks, thigh or outer upper arm. If there’s no response after 15 minutes, a second 0.6 mg dose from a new device may be given while waiting for emergency help.

Trial

Nielsen 2023

Low blood sugar after gastric bypass: 120 mcg self-injected when glucose fell low, for 4 weeks, cut time below 70 mg/dL by 33% vs placebo in 24 adults. Not approved.

Frequency: Once as needed; a second dose after 15 minutes if no response
Route: Subcutaneous injection (autoinjector or prefilled syringe)
Timing: As soon as severe low blood sugar is recognized; emergency help is called right after the dose (label).
Cycle: A single rescue dose when needed, not a course.
As needed, shown over 26 weeks

Common protocols

The ways Dasiglucagon is most often run, each tagged with where it comes from.

Rescue (Zegalogue)

Label

Dose: 0.6 mg
How often: Once; a second dose after 15 minutes if no response
How long: Single emergency use

Ready to use, with no mixing. Approved for adults and for anyone with diabetes weighing at least 20 kg.

Lows after gastric bypass (trial)

Trial

Dose: 120 mcg
How often: Self-injected when glucose fell low
How long: 4 weeks

Crossover trial in 24 adults: 97% of lows corrected within 15 minutes vs 29% on placebo. Not approved.

Mild lows in type 1 diabetes (trial)

Trial

Dose: 80 mcg by pen
How often: As needed for impending or mild lows
How long: 2 weeks

Phase 2 crossover in 24 adults on insulin pumps: recovery 44% faster and 11% less carbohydrate eaten than usual care. Not approved.

Taking it

Where it goes

Under the skin of the lower belly, buttocks, thigh or outer upper arm (label).

If you miss a dose

Not applicable: it’s used once in an emergency. The label says to call for emergency help right after the dose, give a second dose from a new device after 15 minutes if there’s no response, and give sugar by mouth once the person responds.

Missed doses for every compound

What to expect

About 10 minutes
Median time to recovery (a rise of at least 20 mg/dL) was 10 minutes vs 35–40 minutes on placebo in two adult trials, and 12 minutes with standard glucagon.
Label
90 minutes
Blood sugar was an average 168 mg/dL above its starting level in adults with type 1 diabetes.
Label
Within 12 hours
Nausea in 57% and vomiting in 25% of adults, vs 4% and 2% on placebo.
Label

Side effects and what to do

Nausea (label: 57% vs 4% on placebo, adults)

Most common reaction; the instructions say to roll an unconscious person onto their side in case they vomit.

Vomiting (label: 25% vs 2%)

Turning the person on their side prevents choking. Food by mouth once they can swallow.

Headache (label: 11% vs 4%)

Reported within 12 hours of the single dose.

Diarrhea (5% vs 0%) and injection-site pain (2% vs 0%)

Short-lived reactions in the 12 hours after the dose in the trials.

Blood pressure changes, slow heartbeat, palpitations or near-fainting (label)

Reported within 12 hours; with beta-blockers, pulse and blood pressure may rise briefly.

Stop and get medical help

Emergency help is called right after every rescue dose (label). Hives, swelling of the face or throat, trouble breathing or fainting after a dose needs immediate care.

Can it cause …?

The side effects people ask about most, answered one by one. Each answer says where it comes from.

Tiredness: Not reportedTiredness isn’t listed; the adult placebo-controlled trials followed 116 people for 12 hours after a single dose.
Headache: LabelHeadache: 11% vs 4% on placebo in adults, within 12 hours of a dose.
Nausea or vomiting: LabelNausea 57% and vomiting 25% vs 4% and 2% on placebo in adults, within 12 hours. The instructions say to roll an unconscious person onto their side.
Diarrhea or constipation: LabelDiarrhea: 5% vs 0% on placebo in adults, within 12 hours of a dose.
Dizziness: LabelNear-fainting, low blood pressure and dizziness on standing up (orthostatic intolerance) were reported within 12 hours of a dose.
Trouble sleeping: Not reportedTrouble sleeping isn’t listed; the adult trials followed 116 people for 12 hours after one dose.
Hair loss: Not reportedHair loss isn’t listed; the trials gave single doses.
Acne, rash or skin changes: LabelInjection-site pain: 2% vs 0% on placebo. A newborn on long-term pump infusion developed necrolytic migratory erythema, a blistering rash (case report).
Water retention or swelling: Not reportedFluid retention isn’t listed in the label’s placebo-controlled trials of 116 adults given single doses.
Joint or muscle pain: Not reportedJoint or muscle pain isn’t listed in the adult single-dose trials.
Anxiety, low mood or irritability: Not reportedMood changes aren’t listed in the adult single-dose trials.
Low or high blood sugar: LabelIt raises blood sugar, by design: 168 mg/dL above baseline at 90 minutes in adults. Lows can follow with insulinoma or indomethacin, the label warns.
Fast heartbeat or blood pressure changes: LabelHigh or low blood pressure, a slow heartbeat and palpitations were reported within 12 hours. It didn’t prolong QT at over 5 times the usual blood level.
More hunger: Not reportedHunger isn’t listed; the label advises eating once the person responds, to restore liver sugar.
Liver strain: LabelLiver strain isn’t listed. It works by making the liver release stored sugar, so it may fail when those stores are low.
Kidney problems: Not reportedKidney problems aren’t listed in the label; it’s broken down in the blood, liver and kidneys, like glucagon.
Cancer risk: LabelA 26-week study in cancer-prone transgenic mice found it wasn’t carcinogenic (2026 label). It can provoke hormone release from pheochromocytoma or insulinoma, which rule it out.

Label: from the prescribing information. Not reported: studied in people and not reported. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.

Who should avoid it

What its label rules out or warns about, most important first.

Pheochromocytoma (an adrenal tumor): LabelRuled out: it may make the tumor release adrenaline-like hormones and sharply raise blood pressure.
Insulinoma (an insulin-making tumor): LabelRuled out: blood sugar may rise at first, then fall as the tumor releases extra insulin.
Starvation, adrenal insufficiency or chronic lows: LabelIt may not work because the liver’s sugar stores are too low; the label advises glucose instead.
Allergy to glucagon products or latex: LabelAllergic reactions, including anaphylactic shock, have been reported with glucagon products, and the device caps contain dry natural rubber, a latex derivative.
Pregnancy: LabelNo human data. In rabbits it caused fetal malformations at 20 or more times the human exposure; the label notes that untreated severe lows in pregnancy can be fatal.
Children under 20 kg: LabelNot established for severe lows below 20 kg, and not approved at all for congenital hyperinsulinism.

Interactions

Only interactions stated on a product label or measured in a human study are listed.

Beta-blockers (such as metoprolol or propranolol): LabelPulse and blood pressure may rise briefly after a dose, the label says.
Indomethacin: LabelDasiglucagon may lose its ability to raise blood sugar, or may even cause low blood sugar.
Warfarin: LabelDasiglucagon may strengthen warfarin’s effect on blood clotting.

Label: a product label rules it out, warns about it or lists the interaction. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.

Special situations

What the label and studies say about pregnancy, breastfeeding, kidney and liver problems, age and surgery.

Pregnancy: LabelNo human data. In rabbits it caused fetal malformations at 20 or more times the human exposure; the label notes that untreated severe lows in pregnancy can be fatal.
Breastfeeding: LabelNo data on milk transfer. As a peptide it would be digested in the baby’s gut, so the label considers harm unlikely.
Kidney problems: LabelThe label gives no dose change and doesn’t address kidney disease; dasiglucagon is broken down like glucagon, in the blood, liver and kidneys.
Liver problems: LabelNot addressed in the label, but it needs sugar stored in the liver: it may not work in starvation, adrenal insufficiency or chronic lows.
Older adults: LabelThe trials included too few people 65 and older to tell whether they respond differently.
Children and teens: LabelApproved for children and teens with diabetes who weigh at least 20 kg (since June 2026; before that, age 6 and up). Not approved for congenital hyperinsulinism. Vial Guide doesn’t show children’s doses.
Surgery and anesthesia: PrecautionNo label advice. Nausea and vomiting are common after a dose, so tell the surgical or sedation team if it was given recently.

Label: what the prescribing information says. Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.

Tracking and pairing

Worth tracking

Response at 15 minutes (a second dose if none)
Blood sugar after the person eats
Pulse and blood pressure if taking a beta-blocker
Unusual bruising or bleeding if taking warfarin

Often paired with

Usually run on its own.

Human studies

5 key published human studies, with how many people took part. Animal studies aren’t listed here.

2021170 people

Median recovery 10 minutes vs 40 on placebo and 12 with glucagon; 99% recovered within 15 minutes vs 2% on placebo.

Design
Randomized double-blind placebo-controlled trial, with standard glucagon as reference
Dose
0.6 mg under the skin (vs placebo or 1 mg glucagon)
Length
Single dose during an insulin-induced low

Pieber et al., Diabetes Care 2021, PMID 35239971
202145 people

Median recovery 10 vs 35 minutes; 88% recovered within 15 minutes vs none on placebo; buttock or upper-arm injection made no difference.

Design
Randomized double-blind placebo-controlled trial (autoinjector)
Dose
0.6 mg under the skin
Length
Single dose during an insulin-induced low

Bailey et al., Diabetes Obes Metab 2021, PMID 34169625
202324 people

Time below 70 mg/dL fell 33% and below 54 mg/dL 54% vs placebo; 97.3% of lows corrected within 15 minutes vs 29.1%.

Design
Randomized double-blind placebo-controlled crossover trial in adults after gastric bypass
Dose
120 mcg self-injected as needed
Length
Two 4-week periods

Nielsen et al., Diabetes Care 2023, PMID 37819999
202324 people

Recovery from lows was 44% faster and daily carbohydrate intake 11% lower than with usual care; time below range didn’t differ significantly.

Design
Phase 2 randomized open-label crossover trial in adults with type 1 diabetes on insulin pumps
Dose
80 mcg by pen as needed
Length
Two 2-week periods

Laugesen et al., Diabetologia 2023, PMID 37037948
202110 people

Time below 54 mg/dL 0.2% vs 0.6% with insulin alone; time in range (70–180 mg/dL) 79% vs 72%.

Design
Open-label random-order crossover home-use study of a dual-hormone pump in adults with type 1 diabetes
Dose
Automated microdoses (mean 0.35 mg a day) with insulin
Length
7 days per pump setup

Castellanos et al., Diabetes Care 2021, PMID 33906916

All human studies on Vial Guide

Trials under way

Registered trials that are still running, or that finished without published results, most important first. Checked on ClinicalTrials.gov, October 7, 2026.

Phase 3NCT06588504
Dasiglucagon vs glucagon for insulin-induced lows in 38 Asian adults with type 1 diabetes, plus Japanese teens (Novo Nordisk)
Completed July 2025; no results posted
Phase 3NCT03941236
Long-term safety extension of pump-infused dasiglucagon in 42 children with congenital hyperinsulinism
Completed May 2026; no results posted
Phase 3NCT05378672
Single rescue dose in 8 children under 6 with type 1 diabetes, the basis of the June 2026 label change
Completed December 2024; results posted on the registry, no journal paper found

Every compound’s registered trials: trials under way.

Limits of the evidence

Approval rests on three placebo-controlled single-dose trials in people with type 1 diabetes whose blood sugar was lowered with insulin in a clinic (170 and 45 adults, 42 children aged 6–17), plus a small trial in children under 6. None tested real emergencies, type 2 diabetes or many people over 65. Its use for congenital hyperinsulinism and for lows after gastric bypass rests on small trials and isn’t approved.

How it’s supplied

Ready-made pens of 0.6 mg in 0.6 mL: a single-dose autoinjector or prefilled syringe (Zegalogue). The pen measures each dose, so there’s nothing to mix or draw up.

Datasheet

Half-life: about 30 minutes LabelAfter a 0.6 mg injection under the skin; blood levels peak at about 35 minutes.
Type: Peptide, 29 amino acids
Molecular weight: 3381.6 g/mol (free base; the label gives 3382, anhydrous)
Formula: C₁₅₂H₂₂₂N₃₈O₅₀
Sequence: HSQGTFTSDYSKYLD-(Aib)-ARAEEFVKWLESTAib = 2-aminoisobutyric acid; 7 changes from glucagon, at positions 16, 17, 20, 21, 24, 27 and 28
Storage before use: Refrigerate at 2–8 °C, away from the cooling element; never freeze. May instead be kept at 20–25 °C for up to 12 months in its protective case, without going back in the fridge.
After mixing or opening: Single use: each device holds one dose and is discarded after use, or at the end of 12 months at room temperature.

Half-life: Zegalogue prescribing information rev. 06/2026, section 12.3
Molecule: Zegalogue label rev. 06/2026, section 11 (formula, MW); FDA GSRS UNII AD4J2O47FQ and KEGG D11359 (sequence); PubChem CID 126961379
Storage: Label Zegalogue prescribing information rev. 06/2026, section 16.2

Every compound side by side: the half-life chart and the storage chart.

Identifiers

CAS number: 1544300-84-6
UNII (FDA): AD4J2O47FQ
PubChem CID: 126961379
DrugBank: DB15226
ATC code: H04AA02
Development codes: ZP4207, ZP-GA-1
Brand names: Zegalogue (US and EU)
First described: Developed by Zealand Pharma (ZP4207); first approved as Zegalogue in the US in March 2021.

Every compound’s numbers: the identifiers table.

Product form and quality

Each Zegalogue device holds 0.63 mg of dasiglucagon, as the hydrochloride salt, in a ready-to-use water-based solution, to deliver 0.6 mg; nothing is mixed. The 0.6 mg dose isn’t interchangeable with glucagon’s 1 mg.

Cautions

Ruled out with pheochromocytoma (risk of a sharp rise in blood pressure) or insulinoma (risk of a later drop in blood sugar).
May not work when the liver’s sugar stores are low: starvation, adrenal insufficiency or long-standing low blood sugar.
Nausea (57%) and vomiting (25%) were common within 12 hours in adult trials, vs 4% and 2% on placebo.
Allergic reactions, including anaphylaxis, have been reported with glucagon products; the device caps contain dry natural rubber (latex).
Novo Nordisk ended US sales in January 2026 and FDA lists both presentations as discontinued, so supply may be hard to find.

Questions

What is dasiglucagon?

How does dasiglucagon work?

Dasiglucagon is a lab-made version of glucagon with 7 of its 29 amino acids changed so it stays stable in a water-based solution. Like glucagon, it binds glucagon receptors on liver cells, which break down stored sugar (glycogen) and release glucose into the blood; in the trials blood sugar recovered in a median 10 minutes. It needs sugar stored in the liver to work. Effects of long-term pump infusion, studied only in children with congenital hyperinsulinism, are still being assessed; one newborn developed necrolytic migratory erythema, a severe rash. How people over 65 respond is unknown.

Is dasiglucagon FDA-approved?

Approved in the US in March 2021 as Zegalogue for severe low blood sugar in diabetes; since June 2026 the label covers adults and children who weigh at least 20 kg. Novo Nordisk ended US sales in January 2026 and FDA lists both presentations as discontinued; it isn’t approved for congenital hyperinsulinism.

What is the usual dasiglucagon dose?

From the label (Zegalogue): 0.6 mg injected under the skin of the lower belly, buttocks, thigh or outer upper arm. If there’s no response after 15 minutes, a second 0.6 mg dose from a new device may be given while waiting for emergency help. From human studies (Nielsen 2023): Low blood sugar after gastric bypass: 120 mcg self-injected when glucose fell low, for 4 weeks, cut time below 70 mg/dL by 33% vs placebo in 24 adults. Not approved. These are the amounts sources reference, not recommendations.

How is dasiglucagon given?

Ready-made pens of 0.6 mg in 0.6 mL: a single-dose autoinjector or prefilled syringe (Zegalogue), injected under the skin. As soon as severe low blood sugar is recognized; emergency help is called right after the dose (label). The pen measures each dose, so there’s nothing to mix.

Who should avoid dasiglucagon?

Pheochromocytoma (an adrenal tumor): Ruled out: it may make the tumor release adrenaline-like hormones and sharply raise blood pressure. Insulinoma (an insulin-making tumor): Ruled out: blood sugar may rise at first, then fall as the tumor releases extra insulin. Starvation, adrenal insufficiency or chronic lows: It may not work because the liver’s sugar stores are too low; the label advises glucose instead. The “Who should avoid it” section lists 3 more groups and 3 interactions.

What is the half-life of dasiglucagon?

About 30 minutes, according to the prescribing information. After a 0.6 mg injection under the skin; blood levels peak at about 35 minutes.

How should dasiglucagon be stored?

Before mixing: Refrigerate at 2–8 °C, away from the cooling element; never freeze. May instead be kept at 20–25 °C for up to 12 months in its protective case, without going back in the fridge. Single use: each device holds one dose and is discarded after use, or at the end of 12 months at room temperature.

Is dasiglucagon banned in sport?

No. Not named on the 2026 list, and S0 doesn’t apply to an approved drug.

Has dasiglucagon been studied in people?

Yes. The human studies section lists 5 published studies. The largest, from 2021, included 170 people. Median recovery 10 minutes vs 40 on placebo and 12 with glucagon; 99% recovered within 15 minutes vs 2% on placebo.

How long has dasiglucagon been studied in people?

Trial An extension trial in 42 children with congenital hyperinsulinism ran 2019–2026, without posted results. In adults, the longest was 4 weeks of as-needed use after gastric bypass.

Does dasiglucagon come in other forms, like a pill or nasal spray?

Label Only injection under the skin (autoinjector or prefilled syringe) is approved. Continuous pump infusion was tested for congenital hyperinsulinism and in dual-hormone pumps; there’s no nasal or oral form.

Can you drink alcohol while taking dasiglucagon?

Precaution The label doesn’t mention alcohol. Heavy drinking without food can drain the liver’s sugar stores, and the label says it may not work when those stores are low, as in starvation.

Can dasiglucagon be taken with semaglutide or tirzepatide?

Precaution No label lists an interaction, and no study has paired them. GLP-1 drug labels warn of severe lows mainly with insulin or a sulfonylurea, the kind of low dasiglucagon is approved to treat.

What happens if you take too much dasiglucagon?

Label Per the label, overdose may cause nausea, vomiting, slowed gut movement and higher blood pressure and heart rate; potassium can fall. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.

Sources

Zegalogue prescribing information, rev. 06/2026 (FDA supplement approval NDA 214231/S-004, June 2026)
Drugs@FDA: Zegalogue (NDA 214231), approved March 22, 2021; autoinjector and prefilled syringe listed as discontinued
EMA: Zegalogue EPAR (authorized July 24, 2024)
Zealand Pharma Annual Report 2025 (Novo Nordisk agreement ended January 9, 2026; EU withdrawal request; congenital hyperinsulinism refiling) and first-half 2026 results (August 13, 2026)
Zealand Pharma company announcement 48/2024: second complete response letter for congenital hyperinsulinism (October 9, 2024)
Pieber et al., phase 3 trial of dasiglucagon in adults with type 1 diabetes (Diabetes Care 2021) PMID 35239971
Nielsen et al., dasiglucagon for postprandial hypoglycemia after gastric bypass (Diabetes Care 2023) PMID 37819999
Thornton et al., dasiglucagon for congenital hyperinsulinism, phase 3 (J Clin Endocrinol Metab 2024) PMID 37930757

For the protocol details

Zegalogue prescribing information, sections 2, 6, 7, 12 and 14 (rev. 06/2026)
Bailey et al., dasiglucagon by autoinjector, phase 3 (Diabetes Obes Metab 2021) PMID 34169625
Laugesen et al., pen-administered low-dose dasiglucagon (Diabetologia 2023) PMID 37037948

For how it works, who should avoid it and the limits of the evidence

Zegalogue prescribing information, sections 4, 5, 7, 8 and 12 (FDA, rev. 06/2026)
Weschle et al., necrolytic migratory erythema after prolonged dasiglucagon infusion (Endocrinol Diabetes Metab Case Rep 2025) PMID 40300042

For uses, the side-effect questions, special situations, trials, identifiers and status outside the US

Zegalogue prescribing information, sections 1, 6, 8, 10, 12, 13 and 14 (FDA, rev. 06/2026)
De Leon et al., dasiglucagon in infants with congenital hyperinsulinism (J Clin Endocrinol Metab 2025) PMID 39584500
Castellanos et al., bihormonal iLet with dasiglucagon (Diabetes Care 2021) PMID 33906916
Zealand Pharma company announcement 48/2024 (October 9, 2024), Annual Report 2025 and first-half 2026 results (August 13, 2026)
EMA Zegalogue EPAR (authorized July 24, 2024; checked October 2026)
FDA Global Substance Registration System record (UNII AD4J2O47FQ), KEGG D11359 and PubChem CID 126961379
Health Canada Drug Product Database and Australian Poisons Standard, October 2026 (checked October 8, 2026)
ClinicalTrials.gov registry entries for the trials listed (checked October 8, 2026)

By Vial Guide editorsLast reviewed October 7, 2026

How we review